Wyeth, founded in 1860 and headquartered in Madison, New Jersey, is a global biopharmaceutical company dedicated to developing innovative medicines. The company specializes in areas such as vaccines, biologics, and pharmaceuticals, offering a diverse range of products aimed at improving patient health and well-being.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| PFE 5.95% 2037-04-01 USDWyeth | United States | 2037-04-01 | 5.950 | 4.84 |
| PFE 6.00% 2036-02-15 USDWyeth | United States | 2036-02-15 | 6.000 | 4.73 |
| PFE 6.50% 2034-02-01 USDWyeth | United States | 2034-02-01 | 6.500 | 4.48 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Wyeth has a noteworthy history of bond issuances, beginning in the 1980s when it first entered the bond market to fund research and expansion efforts. A significant issuance occurred in 2004, when Wyeth raised $4 billion to support its acquisition strategies and R&D investments. Currently, the company's bond offerings yield competitively compared to industry averages, reflecting strong credit ratings and investor confidence. Notable features of some bonds include callable options, allowing Wyeth to refinance at favorable rates should market conditions improve, and their recent news indicates plans for further issuance to bolster pipeline investments following recent product launches.